[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356586-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356586-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","management-of-adult-patients-with-isocitrate-dehydrogenase-mutant-gliomas-in-australia-expert-position-statement","Management of Adult Patients With Isocitrate Dehydrogenase-Mutant Gliomas in Australia - Expert Position Statement","","Isocitrate dehydrogenase (IDH)-mutant low-grade and high-grade gliomas are primary brain cancers with slower growth and longer survival than IDH-wildtype tumors. Despite this, they remain fatal and often cause major morbidity and productivity loss due to younger patient age. Multiple initial management options exist, but evidence is limited on optimal timing and sequencing. Treatment aims to balance disease control risks against therapy toxicities, prioritizing cognition, neurologic function, and quality of life.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/management-of-adult-patients-with-isocitrate-dehydrogenase-mutant-gliomas-in-australia-expert-position-statement/356586/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/management-of-adult-patients-with-isocitrate-dehydrogenase-mutant-gliomas-in-australia-expert-position-statement/356586.png","ImageObject",300,407,{"name":42,"@type":43},"Kyle","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What distinguishes IDH-mutant gliomas from IDH-wildtype gliomas in terms of behavior and outcome?","Question",{"text":63,"@type":64},"IDH-mutant gliomas generally grow more slowly and are associated with longer survival than IDH-wildtype counterparts. They are still fatal, but the overall course is less rapid.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What treatment approaches are considered after initial diagnosis of IDH-mutant glioma?",{"text":68,"@type":64},"After initial diagnosis, accepted options include continued surveillance, surgical resection, radiotherapy, chemotherapy, and targeted therapies, either alone or in combination.",{"name":70,"@type":61,"acceptedAnswer":71},"Why are treatment decisions emphasized within a multidisciplinary context?",{"text":72,"@type":64},"Because risks from uncontrolled disease must be balanced against potential treatment-related toxicities, and preserving cognition, neurologic function, and quality of life is a priority. The statement also highlights incorporating patient wishes and expectations.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356586,1790244158,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},3985741905716,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Asia-Pacific Journal of  \nClinical Oncology  \nREVIEW   \nManagement of Adult Patients With Isocitrate Dehydrogenase-Mutant Gliomas in Australia: An Expert Position Statement From the Cooperative Trials Group for Neuro-Oncology  \nMark B. Pinkham1, 2, 3  Hao-Wen Sim3, 4, 5, 6  Rosalind L. Jeffree3, 7, 8  Arian Lasocki3, 9, 10, 11  Dianne M. Legge3, 12, 13  Frank Saran3, 14, 15  Laveniya Satgunaseelan16, 17, 18  Hui K. Gan3, 19, 20, 21  \n1 Department of Radiation Oncology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia  2 College of Nursing and Health Sciences, Flinders University, Adelaide, South Australia, Australia  3NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia  4 Faculty of Medicine and Health, University of New South Wales, Kensington, New South Wales, Australia  5 Department of Medical Oncology, The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia  6 Department of Medical Oncology, Chris O’Brien Lifehouse, Camperdown, New South Wales, Australia   \n7 Department of Neurosurgery, Alfred Hospital, Melbourne, Victoria, Australia  8 Department of Surgery, Monash University, Clayton, Victoria, Australia   \n9 Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia  10 Sir Peter Maccallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia  11 Department of Radiology, The University of Melbourne, Parkville, Victoria, Australia  12 Brain Tumour Support Service, Olivia Newton-John Cancer Centre, Austin Health, Heidelberg, Victoria, Australia  13 Faculty of Health Sciences, Curtin University, Bentley, Western Australia, Australia  14 Radiation Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australia  15Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia  16 Department of Neuropathology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia  17 Brain Cancer Research, Chris O’Brien Lifehouse, Camperdown, New South Wales, Australia  18 Faculty of Medicine and Health, School of Medicine, University of Sydney, Camperdown, New South Wales, Australia  19Medical Oncology, Austin Health, Heidelberg, Victoria, Australia  20 Cancer Therapies and Biology Lab, Centre for Research Excellence in Brain Cancer, Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Victoria, Australia  21 Latrobe School of Cancer Medicine, Heidelberg, Victoria, Australia  \nCorrespondence: Hui K. Gan ([hui.gan@austin.org.au](hui.gan@austin.org.au))  \nReceived: 26 October 2025  Accepted: 26 November 2025  \nKeywords: astrocytoma | clinical practice guideline | glioma | IDH-mutant | oligodendroglioma  \nABSTRACT  \nIsocitrate dehydrogenase (IDH)-mutant low-grade and high-grade gliomas are primary brain cancers with slower growth ratesand longer survival than IDH-wildtype counterparts. However, these tumors are fatal and because of the younger age of patients, result in significant morbidity and loss of productivity. Several management options are available at initial diagnosis for IDHmutant gliomas (including close surveillance, surgery, radiation therapy, chemotherapy and/or targeted therapies either alone or in combination), however, there is limited data about optimal timing and sequencing. When considering treatment, the risks associated with uncontrolled disease should be weighed against potential treatment-associated toxicities given the expected long overall survival times for many patients. Preservation of cognition, neurological function and quality of life remain a priority. Treatment decisions should therefore be made in the context of a neuro-oncology multidisciplinary team, and incorporating the patient’s wishes and expectations. The management of recurrent IDH-mutant glioma is not well defined. This expert position statement aims to provide an Australian perspective on the evidence base and available treatments for c","cbCaitqqqHvYUyE2","https://ap.wps.com/l/cbCaitqqqHvYUyE2","pdf",1189545,12,"English","# Abstract\n# Introduction\n## WHO classification and IDH mutation screening\n## Clinical features and grading of IDH-mutant gliomas","[{\"question\":\"What distinguishes IDH-mutant gliomas from IDH-wildtype gliomas in terms of behavior and outcome?\",\"answer\":\"IDH-mutant gliomas generally grow more slowly and are associated with longer survival than IDH-wildtype counterparts. They are still fatal, but the overall course is less rapid.\"},{\"question\":\"What treatment approaches are considered after initial diagnosis of IDH-mutant glioma?\",\"answer\":\"After initial diagnosis, accepted options include continued surveillance, surgical resection, radiotherapy, chemotherapy, and targeted therapies, either alone or in combination.\"},{\"question\":\"Why are treatment decisions emphasized within a multidisciplinary context?\",\"answer\":\"Because risks from uncontrolled disease must be balanced against potential treatment-related toxicities, and preserving cognition, neurologic function, and quality of life is a priority. The statement also highlights incorporating patient wishes and expectations.\"}]","Management of Adult Patients With Isocitrate Dehydrogenase-Mutant Gliomas in Australia - Expert Position Statement | PDF",1790126065,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c9dbd3d0928ce74d637442f544e48eb9.webp",983,1283,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bfd14448b03627c26cd6e9e31a4e9637.webp",982,1281,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/01fa79c30611bcc3b782785e9df8f7fb.webp",981,1280,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e6f5b2b5a7f3cba2916d463092826e1.webp",980,1279]